“It didn't happen overnight. The way we built the program was an iterative process,” says Shubham Gupta, MD.
In this video, Shubham Gupta, MD, summarizes elements of the interactive learning course “Building a Gender Affirmation Program: The What, Why, and How?” which was presented at the North Central Section of the American Urological Association Annual Meeting in Chicago, Illinois. Gupta is director of the Surgical Gender Affirmation Program, Urology Institute, University Hospitals, division chief of Reconstructive Urology at UH Cleveland Medical Center, and associate professor at Case Western Reserve University School of Medicine.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.